Table 4.
The diagnosis value of IGF2BPs in different cancers.
| Cancer type | IGF2BPs | Role of IGF2BPs in cancer diagnosis | Number of cases | References |
|---|---|---|---|---|
| Salivary gland tumors | 3 | Not a specific diagnostic marker for distinguishing salivary gland tumors | 36 | 196 |
| LSCC | 3 | Has good specificity and sensitivity for diagnosis of LSCC, but could not differentiate between carcinoma in situ and invasive carcinoma | 238 | 197 |
| ATC | 1 | Distinguishes ATC from another thyroid carcinoma of follicular origin | 365 | 33 |
| Follicular patterned thyroid tumors | 3 | Distinguishes malignant from benign follicular thyroid lesions | 219 | 251 |
| Papillary thyroid carcinoma | 3 | Inability to differentiate papillary carcinoma from benign lesions; sensitivity is 27% and specificity is 100% | 84 | 198 |
| Esophageal adenocarcinoma | 3 | Can diagnosis invasive esophageal adenocarcinoma and high-grade dysplasia | 217 + 76 | 252,253 |
| Extrapulmonary small cell carcinoma | 3 | Distinguishes small cell carcinoma from carcinoid tumor | 75 | 254 |
| Pancreatic carcinoma | 3 | A sensitive and specific marker for pancreatic ductal carcinoma and high-grade dysplastic lesions | 72 | 255 |
| PDAC | 3 | Distinguishes PDAC from chronic sclerosing pancreatitis and can be used in core needle biopsies; sensitivity is 88.4% and specificity is 94.6% | 240 | 190 |
| Malignant pancreatic cancers | 3 | Combined with IGF2BP3 immunostaining, the sensitivity, specificity, and accuracy of cytohistological analysis significantly increased to 87.9%, 100%, and 90.8% | 215 | 191 |
| Intraductal papillary mucinous neoplasm of the pancreas | 3 | Sensitivity for distinguishing cancerous from noncancerous lesions is 76.1% and specificity is 100% | 205 | 192 |
| Gastric adenocarcinoma | 3 | Distinguishes metastatic adenocarcinoma cells from reactive mesothelial cells in effusions; sensitivity is 78.4% and specificity is 92.5% | 156 | 194 |
| HCC | 3 | Seem to be of limited use as a single marker for the diagnosis; sensitivity is 52% and specificity is 97.1% | 452 | 199 |
| Cholangiocarcinoma | 3 | Distinguishes biliary cancer from the benign specimen (sensitivity is 76.4% and specificity is 80.9%); sensitivity is 89.7% and specificity is 91.7% when using IGF2BP3 and/or histology | 119 | 256 |
| Cholangiocarcinoma | 3 | Distinguishes biliary cancer from the benign specimen (sensitivity is 69.2% and accuracy is 80.0%); sensitivity is 80.8% and accuracy is 87.5% when combining IGF2BP3, EZH2, and p53 | 51 | 257 |
| Cholangiocarcinoma | 3 | Diagnosing the presence of invasion in bile duct biopsies | 37 | 258 |
| Extrahepatic bile duct carcinoma | 3 | Useful in the diagnosis of extrahepatic bile duct carcinoma; sensitivity is 79.4% and specificity is 91.7% | 80 | 259 |
| CRC | 2 | The specificity of anti-IGF2BP2 autoantibodies in serum to detect colon cancer is 97.1%, but the sensitivity is only 23.4% | 140 | 195 |
| CRC | 3 | Combination of histological features and IGF2BP3 increase the sensitivity (95.7%) and negative predictive values (61.1%) for detecting CRC in biopsy specimens | 1131 | 193 |
| Pelvic serous carcinoma | 3 | Could serve as a latent precancer biomarker | 316 | 260 |
| Endometrial carcinoma | 3 | IGF2BP3 together with L1CAM represent the optimal combination for discrimination between low- and high-grade endometrial carcinoma compared with IGF2BP3 or L1CAM alone | 378 | 261 |
| Teratoma | 3 | Might help diagnose metastatic mature teratoma and seminoma | 178 | 262 |
| Teratoma | 3 | Useful in the diagnosis of benign and malignant teratoma | 37 | 263 |
| Serous tubal carcinoma | 3 | Served as a complimentary biomarker to the diagnosis of serous tubal intraepithelial carcinoma | 170 | 264 |
| B-all | 1 | 95% sensitivity and 86% specificity for the diagnosis of ETV6-RUNX1 translocation-positive B-ALL | 143 | 265 |
| Angiosarcoma | 3 | Distinguish between malignant and benign vascular lesions | 71 | 266 |
| Hodgkin lymphoma | 3 | Served as a supplemental diagnostic marker | 81 | 267 |
| Hodgkin lymphoma | 3 | The sensitivity of IGF2BP3 to distinguish Hodgkin lymphoma is 84.3%; CD30/IGF2BP3 differentiates Hodgkin lymphoma with the same sensitivity as CD15/CD30 (traditional markers) | 51 | 268 |
| Leiomyosarcoma | 3 | Distinguishes leiomyoma from leiomyosarcoma | 216 | 269 |
| Chondrosarcoma | 3 | Differentiates problematic cases of enchondroma from well-differentiated chondrosarcomas | 78 | 270 |
ATC: anaplastic thyroid carcinomas; CRC: colorectal cancer; HCC: hepatocellular carcinoma; LSCC: laryngeal squamous cell carcinoma; PDAC: pancreatic ductal adenocarcinoma.